Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Olverembatinib Post-Transplant in Ph+ Leukemia
NCT05604755Phase 2Withdrawn
- Sponsor
- Xuna
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in Philadelphia-chromosome positive acute lymphoblastic leukemia, chronic myeloid leukemia (CML), sponsored by Xuna. Planned start Jan 2022; status: withdrawn.
02
Drugs
olverembatinib
03
Conditions
Philadelphia-chromosome positive acute lymphoblastic leukemiachronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05604755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604755.